# Pembrolizumab

## KEYTRUDA inj 100mg-4mL

*藥物代碼*：IKEY1

*給藥途徑*：I

*用法用量*：

The recommended dose of KEYTRUDA is 2 mg/kg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity.

[OFF-LABLE USE IN TAIWAN]
Colorectal cancer, Unresectable or metastatic, progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan - Microsatellite instability-high, Or mismatch repair deficient : 200 mg IV infusion over 30 minutes every 3 weeks; continue treatment for up to 24 months or until disease progression or unacceptable toxicity
 
Head and neck cancer, Recurrent or metastatic, squamous cell, with disease progression on or after platinum-based chemotherapy : 200 mg IV infusion over 30 minutes every 3 weeks; continue treatment for up to 24 months or until disease progression or unacceptable toxicity
 
Hodgkin's disease, Classical, refractory or relapsed after 3 or more prior lines of therapy : 200 mg IV infusion over 30 minutes every 3 weeks; continue treatment for up to 24 months or until disease progression or unacceptable toxicity

Metastatic urothelial carcinoma, Or locally advanced, in patients not eligible for cisplatin-containing chemotherapy, or with progression during or after platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy : 200 mg IV infusion over 30 minutes every 3 weeks; continue treatment for up to 24 months or until disease progression or unacceptable toxicity
 
Microsatellite instability-high, Or mismatch repair deficient - Solid tumor, Unresectable or metastatic, progressed following prior treatment and who have no satisfactory alternative treatment options : 200 mg IV infusion over 30 minutes every 3 weeks; continue treatment for up to 24 months or until disease progression or unacceptable toxicity

Non-small cell lung cancer, Metastatic, high PD-L1 expression, first-line treatment, with no EGFR or ALK tumor aberrations : 200 mg IV infusion over 30 minutes every 3 weeks; continue treatment for up to 24 months or until disease progression or unacceptable toxicity
 
Non-small cell lung cancer, Metastatic, PD-L1 expression, with disease progression on or after platinum-based chemotherapy; patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving pembrolizumab : 200 mg IV infusion over 30 minutes every 3 weeks; continue treatment for up to 24 months or until disease progression or unacceptable toxicity
 
Nonsquamous non-small cell lung cancer, Metastatic, first-line treatment in combination with pemetrexed and carboplatin : 200 mg IV infusion over 30 minutes every 3 weeks, for up to 24 months or until disease progression or unacceptable toxicity. Give prior to pemetrexed 500 mg/m(2) IV and carboplatin AUC 5 mg/mL/min IV on day 1 of each 21-day cycle for 4 cycles, followed by pembrolizumab monotherapy with or without pemetrexed maintenance.


